Irinotecan Sun (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is metabolised inside cancer cells to SN‑38, an active metabolite that inhibits topoisomerase I. This enzyme normally relieves torsional strain during DNA replication; its inhibition leads to persistent single‑strand DNA breaks, triggering apoptosis of rapidly dividing tumor cells.

The dose of Irinotecan Sun is individualized by the prescribing oncologist based on factors such as body surface area, liver function, prior chemotherapy exposure, and the specific treatment protocol. No fixed regimen is provided here; dosing decisions are made by qualified healthcare professionals.

Safety data for Irinotecan Sun in pregnancy and lactation are limited. The drug is generally avoided unless the potential therapeutic benefit outweighs the possible risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose.

To place an order, submit an enquiry on the Irinotecan Sun product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from agents such as oxaliplatin or taxanes. Compared with older regimens, irinotecan‑based combinations often provide higher response rates in colorectal cancer, especially after fluoropyrimidine failure, but they may also carry a different toxicity profile, notably diarrhea and neutropenia.

Irinotecan Sun should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not store at room temperature for extended periods.

Irinotecan Sun is given as an intravenous infusion, typically over 30 to 90 minutes depending on the protocol. The infusion is performed by qualified healthcare personnel in a clinical setting, with appropriate monitoring for infusion‑related reactions and supportive care measures.

The most critical adverse events include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea that can progress to colitis or intestinal perforation, and rare allergic reactions. Prompt recognition and management of these complications are essential to reduce morbidity.

Irinotecan Sun is contraindicated in patients with known hypersensitivity to irinotecan or any of its excipients, in those with severe bone‑marrow suppression, and in individuals with uncontrolled infections. Caution is also advised for patients with significant hepatic impairment or a history of severe gastrointestinal disorders.